SureTrader Advertisement PRTC
Home > Boards > US Listed > Medical - Drugs >

Transgenomic Inc. (TBIO)

Add TBIO Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 5/23/2016 1:05:48 PM - Followers: 35 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#955   anybody have any news paxgarmana 05/23/16 01:05:48 PM
#954   $TBIO .57 Added a Few Today. I'm Not PENNYBUSTER 05/03/16 08:31:01 PM
#953   TBIO +22% ash111 04/19/16 03:08:23 PM
#952   anybody know what is going on? paxgarmana 04/17/16 11:19:34 PM
#951   if this company guts current leadership, maybe. paxgarmana 03/18/16 05:14:07 PM
#950   Sickening! Tstorm 03/18/16 04:01:47 PM
#949   not the best close reason for this decline. ash111 03/18/16 03:56:53 PM
#948   Transgenomic Inc rockets as market hails new cancer assay phicour 03/18/16 12:33:03 PM
#947   TBIO seems to be holding gains. Thats phicour 03/18/16 12:09:42 PM
#946   $TBIO recent news/filings stocktrademan 03/18/16 11:26:30 AM
#945   First 5 minute candle was red. That was OB_WEALTH_INC 03/18/16 11:12:38 AM
#944   20 times average volume ash111 03/18/16 09:58:36 AM
#943   could see even 2 after profits taking imo ash111 03/18/16 09:30:11 AM
#942   TBIO here we go....Will buy breakout at 1.08..will OB_WEALTH_INC 03/18/16 09:23:21 AM
#941   1.05 PM going,nice volume already over average volume. ash111 03/18/16 09:15:38 AM
#940   TBIO Should break a buck fast imo.ransgenomic Launches ash111 03/18/16 08:56:34 AM
#939   TBIO huge news out going pm ash111 03/18/16 08:16:51 AM
#938   well, TBIO got rid of New Haven. paxgarmana 03/17/16 03:44:34 PM
#937   .73 green,hod close,on a bloody day for most ash111 03/15/16 04:02:15 PM
#936   Only a few millions float. Still holding mine. ash111 03/14/16 12:54:59 PM
#935   If Kinnon is out, I'm in paxgarmana 03/11/16 05:09:35 PM
#934   If a buy out is brewing I guess ash111 03/11/16 03:59:47 PM
#933   news out - Transgenomic Launches New MX-ICP Liquid ash111 03/10/16 07:52:23 AM
#932   actually Kirk Randal control the company. the filler ash111 03/09/16 03:16:58 PM
#931   I will keep my eyes on this. paxgarmana 03/09/16 03:13:50 PM
#930   happening these days imo check insiders actions.cap and ash111 03/09/16 03:08:56 PM
#929   should have happened last year - I'd have paxgarmana 03/09/16 03:07:50 PM
#928   power struggle in the works ash111 03/09/16 03:06:36 PM
#927   re #7 paxgarmana 03/09/16 03:01:14 PM
#926   nice bids,if break MA50,next stop is a buck imo: ash111 03/09/16 12:35:49 PM
#925   Doing more DD,"The units were sold to the ash111 03/08/16 02:23:31 PM
#924   TBIO might have a new Management soon(or a ash111 03/08/16 01:51:22 PM
#923   TBIO going soon UHD 03/08/16 01:40:44 PM
#922   Time is running out UHD 03/08/16 01:40:04 PM
#921 ash111 03/08/16 11:33:19 AM
#920   I hope so - for everybody's sake paxgarmana 03/08/16 11:33:01 AM
#919   i think TBIO will have a new owner ash111 03/08/16 11:28:57 AM
#918   dude, I am just giving my opinion. paxgarmana 03/08/16 11:27:14 AM
#917   Given $7.00 Consensus Target Price by Brokerages,crossed both ash111 03/08/16 11:22:20 AM
#916   yup paxgarmana 03/08/16 11:21:25 AM
#915   so you have been holding and sold. and ash111 03/08/16 11:19:15 AM
#914   normally I would agree with you paxgarmana 03/08/16 11:17:27 AM
#913   good luck,sold too early? and forgot the huge ash111 03/08/16 11:15:36 AM
#912   guys - I have followed TBIO for paxgarmana 03/08/16 10:32:07 AM
#911   guys - I have followed TBIO for paxgarmana 03/08/16 10:28:24 AM
#910   agree.not only the 54% stake, third sec owns ash111 03/08/16 09:44:40 AM
#909   Good Volume. Accumulated Shares of $TBIO through Feb. GalacticGreen 03/08/16 05:43:51 AM
#908   TBIO looking primed for a run UHD 03/07/16 07:26:52 PM
#907   interesting post ou81 ash111 03/07/16 02:57:06 PM
#906   crossed both the 8DMA or the 34DMA ash111 03/07/16 01:50:51 PM